Screener
TG Therapeutics TGTX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $213,693 | $107,508 |
| Other current liabilities | 857 | 2,124 |
| Lease liability – current portion | 1,913 | 1,044 |
| Deferred revenue - current portion | 16,825 | 21,234 |
| Accrued compensation | 35,205 | 21,850 |
| Total current liabilities | 268,493 | 153,760 |
Document
FAQ
- What is TG Therapeutics's accrued expenses?
- TG Therapeutics (TGTX) reported accrued expenses of $857K in Q2 2026.
- How has TG Therapeutics's accrued expenses changed year-over-year?
- TG Therapeutics's accrued expenses decreased by 62.0% year-over-year, from $2.26M to $857K.
- What is the long-term trend for TG Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), TG Therapeutics's accrued expenses has grown at a -35.0% compound annual growth rate (CAGR), from $18.24M to $2.12M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about TG Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude